Grant-Funded Projects for Early Stage Research

Government and foundation grants are often the first mechanisms available to entrepreneurs to establish the validity of their research programs and to demonstrate feasibility of a novel approach. However, like many early stage projects in drug discovery, expert medicinal chemistry is often required to transform a biological concept into a project with future drug development potential. Provid has a track record of successful NIH grants and contracts and foundation funding for projects originating in Provid’s own internal programs as well as those from academic groups and small companies.

The biological and chemistry concepts elaborated in a grant proposal also must be of exceptional merit to be funded in the current environment. Provid has the experience and capability to serve as PI or a collaborator on grant proposals for NIH including SBIR/STTR and R01, with drug discovery chemistry that is judged to be of high quality by NIH reviewers.

List of grants funded to date for internal and client projects:

  • NIAID SBIR:  Infectious disease, targeting RNA polymerase specifically in bacteria (Rutgers/HHMI)
  • NINDS SBIR:  Multiple sclerosis, MHC class II DR2 inhibitors blocking antigen presentation (Case Western, UTSA)
  • Fast Forward/NMSS:  PV-267 for multiple sclerosis (UTSA)
  • NJEDA:  Autoimmune disease (Springboard Fund)
  • NHLBI SBIR: Inhibitors of PKA localization in heart (Sequenom/UCSD)
  • NIDDK STTR: Celiac disease, MHC class II DQ2 inhibitors
  • NINDS STTR:  Huntington’s disease, inhibitors of polyQ aggregation (Duke)
  • NJCST:  Drug design algorithms
  • NHLBI SBIR:  F11R Inhibitors for Atherosclerosis (SUNY Downstate)
  • NIAID R01:  Infectious disease target, Provid subcontract (Rutgers)
  • IRS/Qualifying Therapeutic Discovery Project Grant: Development of PV-267, a DR2 inhibitor for the treatment of multiple sclerosis.

Abbreviations:  NIAID (National Institute of Allergy and Infectious Diseases), NINDS (National Institute of Neurological Diseases and Stroke), NMSS (National Multiple Sclerosis Society), NHLBI (National Heart, Lung, and Blood Institute), NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), NJEDA (New Jersey Economic Development Authority), NJCST (New Jersey Commission on Science and Technology).